<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01774370</url>
  </required_header>
  <id_info>
    <org_study_id>1160.139</org_study_id>
    <nct_id>NCT01774370</nct_id>
  </id_info>
  <brief_title>SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea</brief_title>
  <official_title>A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Pradaxa (Dabigatran Etexilate Mesilate, 110 mg or 150 mg b.i.d.) in Korean Patients With Non-valvular Atrial Fibrillation(SPARK: Safety Study of Pradaxa in AF Patients by Regulatory Requirement of Korea)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This is a prospective, non-interventional, open-label, multi-centre study. It will provide
      additional safety information of Pradaxa in Korean patients with non-valvular AF in clinical
      settings.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:

      regulatory PMS study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 14, 2013</start_date>
  <completion_date type="Actual">February 17, 2017</completion_date>
  <primary_completion_date type="Actual">February 17, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of adverse events(Including unexpected adverse events, serious adverse events, drug-related adverse events, adverse events leading to discontinuation and adverse events by intensity, outcome of the event, causality)</measure>
    <time_frame>up to 26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of stroke</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of systemic embolism</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3187</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Pradaxa group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pradaxa (Dabigatran etexilate mesilate)</intervention_name>
    <description>110 mg or 150 mg b.i.d.</description>
    <arm_group_label>Pradaxa group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Korean patients with non-valvular AF
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age &gt;= 18 years at enrollment

          -  Patients who have been started on Pradaxa in accordance with the approved label in
             Korea

          -  Patients who have signed on the data release consent form

        Exclusion criteria:

          -  Patients with previous exposure to Pradaxa

          -  Clinically significant bleeding

          -  Increased risk of bleeding due to following diseases;

               -  Recent gastrointestinal ulceration

               -  Recent intracranial or intracerebral bleeding history

               -  Intraspinal or intracerebral vascular abnormalities

               -  Recent brain, spinal or ophthalmic surgery

               -  Recent brain or spinal injury

               -  Known or suspected oesophageal varices

               -  Arteriovenous malformations

               -  Vascular aneurysms

               -  Presence of malignant neoplasms at high risk of bleeding

          -  Concomitant treatment with any other anticoagulants e.g. unfractionated heparin (UFH),
             low molecular weight heparins (enoxaparin, dalteparin etc), heparin derivatives
             (fondaparinux etc), oral anticoagulants (warfarin, rivaroxaban, apixaban etc) except
             under the circumstances of switching therapy to or from Pradaxa or when UFH is given
             at doses necessary to maintain an open central venous or arterial catheter

          -  Severe renal impairment (CrCl &lt; 30mL/min)

          -  Concomitant treatment with oral ketoconazole or dronedarone

          -  Patients hypersensitive to dabigatran or dabigatran etexilate or to any ingredient in
             the formulation

          -  Prosthetic heart valve replacement

          -  No creatinine clearance collected within at least one year prior to enrollment

          -  Current participation in other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2013</study_first_submitted>
  <study_first_submitted_qc>January 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2013</study_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 8, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

